Table 3.
Pathological features of Xp11.2 translocation and conventional renal cell carcinoma at clinical T1 stage
| Pathological feature | Clinical T1a stage | Clinical T1b stage | ||||
|---|---|---|---|---|---|---|
| Xp11.2 translocation RCC (36 cases) | Conventional RCC (145 cases) | P-value | Xp11.2 translocation RCC (34 cases) | Conventional RCC (128 cases) | P-value | |
| Tumor size, cm (mean ± SD) | 3.27 ± 0.60 | 3.08 ± 0.79 | 0.304 | 5.58 ± 0.74 | 5.56 ± 0.86 | 0.919 |
| Necrosis | 8/36 (22.2%) | 12/145 (8.3%) | 0.036 | 9/34 (26.5%) | 66/128 (51.6%) | 0.009 |
| Sarcomatous | 2/36 (5.6%) | 6/145 (4.1%) | 0.711 | 2/34 (5.9%) | 18/128 (14.1%) | 0.319 |
| Renal capsule | 0.072 | 0.543 | ||||
| Uninvolved | 9/36 (25.0%) | 66/145 (45.5%) | 5/34 (14.7%) | 15/128 (11.7%) | ||
| Involved | 18/36 (50.0%) | 54/145 (37.2%) | 22/34 (64.7%) | 95/128 (74.2%) | ||
| Breakthrough | 9/36 (25.0%) | 25/145 (17.2%) | 7/34 (20.6%) | 18/128 (14.1%) | ||
| Undefined border | 13/36 (36.1%) | 18/145 (12.4%) | 0.001 | 10/34 (29.4%) | 44/128 (34.4%) | 0.585 |
| Surgical margin positivity | 1/18 (5.6%) | 5/121 (4.1%) | 0.782 | 4/12 (33.3%) | 8/93 (8.6%) | 0.040 |
| Adrenal invasion | 0/4 (0%) | 0/1 (0%) | – | 1/8 (12.5%) | 0/8 (0%) | 0.228 |
| Pelvicalyceal invasion | 5/18 (27.8%) | 2/24 (8.3%) | 0.094 | 11/22 (50.0%) | 2/35 (5.7%) | < 0.001 |
| Nerve invasion | 0/18 (0%) | 0/24 (0%) | – | 2/22 (9.1%) | 1/35 (2.9%) | 0.313 |
| Vascular invasion | 1/18 (5.6%) | 0/24 (0%) | 0.189 | 11/22 (50.0%) | 7/35 (20.0%) | 0.018 |
| Venous cancer thrombus | 0/18 (0%) | 3/24 (12.5%) | 0.060 | 4/22 (18.2%) | 4/35 (11.4%) | 0.480 |
| Renal sinus invasion | 1/18 (5.6%) | 2/24 (8.3%) | 0.726 | 2/22 (9.1%) | 4/35 (11.4%) | 0.778 |
| Lymphatic metastasis | 0/5 (0%) | 0/3 (0%) | – | 6/11 (54.5%) | 1/9 (11.1%) | 0.035 |
| Fuhrman grade | < 0.001 | 0.969 | ||||
| I + II | 16/36 (44.4%) | 120/145 (82.8%). | 15/34 (44.1%) | 56/128 (43.8%) | ||
| III + IV | 20/36 (55.6%) | 25/145 (17.2%) | 19/34 (55.9%) | 72/128 (56.3%) | ||